Technical Analysis for DRUG - Bright Minds Biosciences Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Crossed Above 20 DMA | Bullish | 0.91% | |
| Bollinger Band Squeeze | Range Contraction | 0.91% | |
| Gapped Up | Strength | 0.91% | |
| Fell Below 20 DMA | Bearish | 4.72% | |
| Bollinger Band Squeeze | Range Contraction | 4.72% | |
| Inside Day | Range Contraction | 4.72% | |
| Crossed Above 20 DMA | Bullish | 2.30% | |
| Bollinger Band Squeeze | Range Contraction | 2.30% | |
| Doji - Bullish? | Reversal | 2.30% | |
| Fell Below 20 DMA | Bearish | 3.74% |
| Alert | Time |
|---|---|
| Up 1% | about 2 hours ago |
| 60 Minute Opening Range Breakout | about 2 hours ago |
| Gap Up Closed | 3 days ago |
| 20 DMA Resistance | 3 days ago |
| Reversed from Up | 3 days ago |
Free Daily (Stock) Chart Reading
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 08/28/2023
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was incorporated in 2019 and is headquartered in Vancouver, Canada.
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Pain Organic Compounds Chemical Compounds Epilepsy Antidepressants Neurotransmitters Treatment Of Epilepsy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Drugs Pain Organic Compounds Chemical Compounds Epilepsy Antidepressants Neurotransmitters Treatment Of Epilepsy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 6.44 |
| 52 Week Low | 0.93 |
| Average Volume | 19,707 |
| 200-Day Moving Average | 1.65 |
| 50-Day Moving Average | 1.19 |
| 20-Day Moving Average | 1.07 |
| 10-Day Moving Average | 1.08 |
| Average True Range | 0.10 |
| RSI (14) | 47.64 |
| ADX | 24.28 |
| +DI | 12.30 |
| -DI | 16.71 |
| Chandelier Exit (Long, 3 ATRs) | 0.94 |
| Chandelier Exit (Short, 3 ATRs) | 1.22 |
| Upper Bollinger Bands | 1.15 |
| Lower Bollinger Band | 0.99 |
| Percent B (%b) | 0.68 |
| BandWidth | 15.40 |
| MACD Line | -0.04 |
| MACD Signal Line | -0.05 |
| MACD Histogram | 0.016 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.20 | ||||
| Resistance 3 (R3) | 1.20 | 1.16 | 1.19 | ||
| Resistance 2 (R2) | 1.16 | 1.13 | 1.16 | 1.18 | |
| Resistance 1 (R1) | 1.13 | 1.12 | 1.11 | 1.13 | 1.18 |
| Pivot Point | 1.09 | 1.09 | 1.08 | 1.09 | 1.09 |
| Support 1 (S1) | 1.06 | 1.06 | 1.04 | 1.07 | 1.02 |
| Support 2 (S2) | 1.02 | 1.05 | 1.02 | 1.02 | |
| Support 3 (S3) | 0.99 | 1.02 | 1.01 | ||
| Support 4 (S4) | 1.00 |
